PrognomIQ

San Mateo, CA · Founded 2020 · Privately Held (backing)

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. PrognomIQ is based in San Mateo, CA and was founded in 2020. It is valued at about $316 million as of Oct 2026, set by institutional fund marks. It has raised $172 million across 3 recorded rounds; the latest was an $11.9 million early-stage round in Jan 2026.

PMV mark · valuation
$315.6M
Oct 2026
Priced at
—
Total raised
$171.8M
Last round
Early Stage VC
Jan 2026
What is PrognomIQ worth?
$315.6MPrivateMarketView mark · Oct 2026

Reported valuation; nothing comparable since.

Pro
The prices on PrognomIQ
  • ·5 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

PrognomIQ funding history

3 rounds
DateRoundRaisedPost-money
Jan 2026Early Stage VC$11.9M▮
Aug 2025Early Stage VC$10.0M▮
Aug 2024Early Stage VC$34.3M▮
Unlock post-money valuations

Membership and data by Private Market View

PrognomIQ valuation

PrognomIQ is valued at approximately $316 million as of Oct 2026. The figure is set by institutional fund marks.

How much has PrognomIQ raised?

PrognomIQ has raised $172 million in total; 3 of its rounds are on record, from 2024 on. The largest on record was a $34.3 million early-stage round in Aug 2024; the most recent was an $11.9 million early-stage round in Jan 2026.

PrognomIQ has filed 2 Form Ds with the SEC since 2024, most recently in Aug 2025 ($10 million sold to 9 investors).

Institutional holders and vehicles

1 SEC-registered fund reported 5 fair-value marks on PrognomIQ between May 2025 and May 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

How PrognomIQ's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For PrognomIQ, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →

Frequently asked about PrognomIQ

What is PrognomIQ worth?
PrognomIQ is valued at $315.6M as of Oct 2026. Reported valuation; nothing comparable since.
How much has PrognomIQ raised?
PrognomIQ has raised $171.8M in total funding across 3 recorded rounds.
When did PrognomIQ last raise?
PrognomIQ last raised in Jan 2026 (Early Stage VC), raising $11.9M.